Healthy Skepticism Library item: 2792

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Avogino T.
Cardiologist Criticizes Merck Behavior
Associated Press 2005 Dec 3
http://abcnews.go.com/Business/wireStory?id=1369882

Keywords:
Topol Vioxx Merck

Notes:

Ralph Faggotter’s Comments:

Eric Topol tackles two important points here-

1/. When did Merck first discover that Vioxx could cause heart attacks?
2/. For how long do you have to take Vioxx before you are at an increased risk of heart attack?

Neither of his answers will please Merck’s lawyers.

Full text:

Cardiologist Criticizes Merck Behavior
By THERESA AGOVINO, AP Business Writer

A prominent cardiologist testifying against Merck & Co. accused the drugmaker Saturday of engaging in scientific misconduct, suppressing clinical evidence and stifling medical discourse as it promoted the painkiller Vioxx.

Dr. Eric Topol, chairman of the cardiovascular medicine department of the Cleveland Clinic, called certain aspects of Merck’s behavior “repulsive” and “appalling” during his three-hour videotaped deposition.

Topol said Vioxx can cause heart attacks any time after a patient begins taking it, and that its risks were apparent as early as 1999, when the drug was approved. Vioxx was removed from the market last year after a study showed it doubled patients’ risk of heart attacks and strokes after 18 months of use.

“Vioxx’s risk has been evident since trails were conducted in 1999 and all the way through the time of withdrawal in September 30, 2004,” Topol said.

This is the first federal trial over Vioxx; Merck has already lost one state trial over the drug and won another, but it still faces about 7,000 lawsuits and analysts estimate its liability could reach $50 billion.

The jurors who heard Topol’s testimony Saturday will be asked to decide if the drug contributed to the fatal heart attack suffered by Richard “Dicky” Irvin in May 2001. The 53-year old former manager of a seafood wholesaler had been taking Vioxx for about a month for back pain.

Merck argues that the drug wasn’t responsible for Irvin’s death, saying problems with Vioxx surface after 18 months of use, not one month, and alleging that plaque in Irvin’s artery ruptured and caused the heart attack, not the drug.

Both sides in the case are under a gag order.

Topol said the concerns about Vioxx caught his eye after he read an article about a study released by Merck in 2000 that found patients taking Vioxx had five times the rate of heart attacks as those taking naproxen, another pain reliever. In the article, Merck explained differences found in that study by saying naproxen is cardioprotective. Topol said naproxen wasn’t associated with such properties.

“To all of a sudden ascribe some type of magical protective effect (to naproxen) without any basis is not acceptable,” he said.

When he compared the U.S. Food and Drug Administration records of the study with the data in the New England Journal of Medicine article, Topol said he found several discrepancies. In particular, he said, the number of deaths and heart attacks were higher in the FDA data. He called the discrepancies “scientific misconduct.”

Topol also said that the company had conducted a trial in 1999 comparing Vioxx to a placebo and nabumetone, another pain reliever, that found Vioxx caused a “760 percent excess rate of heart attacks,” but that the study was never published.

In 2001, as Topol was preparing to have published an article he had written highlighting cardiovascular risk from Vioxx, he received a visit from Dr. Alise Reicin, vice president of clinical research at Merck Research Labs.

According to Topol, Reicin told him he would be “embarrassed” if he published the article because he didn’t have all the data.

After the article was published, he said, Merck sent letters to doctors all over the country saying his analysis was wrong. He was said Merck also attempted to “trash” others who criticized Vioxx.

Topol also testified that Merck’s former chairman Raymond Gilmartin approached the chairman of the Cleveland Clinic to complain about his frequent criticism of Vioxx. Topol referred to that action as “repulsive.”

Topol, who subpoenaed by the plaintiff to testify, declined to comment Saturday but through a spokeswoman said he only wants to be an advocate for scientific integrity and patient safety and doesn’t want to be involved in litigation.

Merck filed a motion to exclude Topol’s deposition but only succeeded in getting certain parts eliminated from what the jury saw. For example, at one point during the deposition, Topol read an e-mail he wrote to a colleague which said he was “bothered by the continued outrageous lies of Merck with their full page, multiple ads that ‘they publish everything’….”

Copyright © 2005 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten or redistributed without the prior written authority of The Associated Press.